These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
834 related articles for article (PubMed ID: 25845492)
1. Parental reporting of response to oral cannabis extracts for treatment of refractory epilepsy. Press CA; Knupp KG; Chapman KE Epilepsy Behav; 2015 Apr; 45():49-52. PubMed ID: 25845492 [TBL] [Abstract][Full Text] [Related]
2. Perceived efficacy of cannabidiol-enriched cannabis extracts for treatment of pediatric epilepsy: A potential role for infantile spasms and Lennox-Gastaut syndrome. Hussain SA; Zhou R; Jacobson C; Weng J; Cheng E; Lay J; Hung P; Lerner JT; Sankar R Epilepsy Behav; 2015 Jun; 47():138-41. PubMed ID: 25935511 [TBL] [Abstract][Full Text] [Related]
3. Duration of use of oral cannabis extract in a cohort of pediatric epilepsy patients. Treat L; Chapman KE; Colborn KL; Knupp KG Epilepsia; 2017 Jan; 58(1):123-127. PubMed ID: 27859038 [TBL] [Abstract][Full Text] [Related]
4. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. Devinsky O; Marsh E; Friedman D; Thiele E; Laux L; Sullivan J; Miller I; Flamini R; Wilfong A; Filloux F; Wong M; Tilton N; Bruno P; Bluvstein J; Hedlund J; Kamens R; Maclean J; Nangia S; Singhal NS; Wilson CA; Patel A; Cilio MR Lancet Neurol; 2016 Mar; 15(3):270-8. PubMed ID: 26724101 [TBL] [Abstract][Full Text] [Related]
5. Long-term safety and efficacy of cannabidiol in children and adults with treatment resistant Lennox-Gastaut syndrome or Dravet syndrome: Expanded access program results. Laux LC; Bebin EM; Checketts D; Chez M; Flamini R; Marsh ED; Miller I; Nichol K; Park Y; Segal E; Seltzer L; Szaflarski JP; Thiele EA; Weinstock A; Epilepsy Res; 2019 Aug; 154():13-20. PubMed ID: 31022635 [TBL] [Abstract][Full Text] [Related]
6. Cannabis for the Treatment of Epilepsy: an Update. Gaston TE; Szaflarski JP Curr Neurol Neurosci Rep; 2018 Sep; 18(11):73. PubMed ID: 30194563 [TBL] [Abstract][Full Text] [Related]
7. Cannabidiol as adjunctive treatment of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome. Lattanzi S; Trinka E; Russo E; Striano P; Citraro R; Silvestrini M; Brigo F Drugs Today (Barc); 2019 Mar; 55(3):177-196. PubMed ID: 30938373 [TBL] [Abstract][Full Text] [Related]
8. Highly Purified Cannabidiol for Epilepsy Treatment: A Systematic Review of Epileptic Conditions Beyond Dravet Syndrome and Lennox-Gastaut Syndrome. Lattanzi S; Trinka E; Striano P; Rocchi C; Salvemini S; Silvestrini M; Brigo F CNS Drugs; 2021 Mar; 35(3):265-281. PubMed ID: 33754312 [TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Cannabidiol in Epilepsy: A Systematic Review and Meta-Analysis. Lattanzi S; Brigo F; Trinka E; Zaccara G; Cagnetti C; Del Giovane C; Silvestrini M Drugs; 2018 Nov; 78(17):1791-1804. PubMed ID: 30390221 [TBL] [Abstract][Full Text] [Related]
10. Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: A systematic review and meta-analysis. Talwar A; Estes E; Aparasu R; Reddy DS Exp Neurol; 2023 Jan; 359():114238. PubMed ID: 36206805 [TBL] [Abstract][Full Text] [Related]
11. Cannabinoids in treatment-resistant epilepsy: A review. O'Connell BK; Gloss D; Devinsky O Epilepsy Behav; 2017 May; 70(Pt B):341-348. PubMed ID: 28188044 [TBL] [Abstract][Full Text] [Related]
12. The role of cannabinoids in epilepsy treatment: a critical review of efficacy results from clinical trials. Nabbout R; Thiele EA Epileptic Disord; 2020 Jan; 22(S1):23-28. PubMed ID: 31916540 [TBL] [Abstract][Full Text] [Related]
13. CBD-enriched medical cannabis for intractable pediatric epilepsy: The current Israeli experience. Tzadok M; Uliel-Siboni S; Linder I; Kramer U; Epstein O; Menascu S; Nissenkorn A; Yosef OB; Hyman E; Granot D; Dor M; Lerman-Sagie T; Ben-Zeev B Seizure; 2016 Feb; 35():41-4. PubMed ID: 26800377 [TBL] [Abstract][Full Text] [Related]
14. Lamotrigine adjunctive therapy among children and adolescents with primary generalized tonic-clonic seizures. Trevathan E; Kerls SP; Hammer AE; Vuong A; Messenheimer JA Pediatrics; 2006 Aug; 118(2):e371-8. PubMed ID: 16847080 [TBL] [Abstract][Full Text] [Related]
15. New therapeutic approach in Dravet syndrome and Lennox-Gastaut syndrome with cannabidiol. Villanueva V; Carreño-Martínez M; Gil Nagel-Rein A; López-González FJ Rev Neurol; 2021 Apr; 72(S01):S1-S10. PubMed ID: 33908026 [TBL] [Abstract][Full Text] [Related]
16. Cannabidiol Therapy for Refractory Epilepsy and Seizure Disorders. Golub V; Reddy DS Adv Exp Med Biol; 2021; 1264():93-110. PubMed ID: 33332006 [TBL] [Abstract][Full Text] [Related]
17. Efficacy of artisanal preparations of cannabidiol for the treatment of epilepsy: Practical experiences in a tertiary medical center. Porcari GS; Fu C; Doll ED; Carter EG; Carson RP Epilepsy Behav; 2018 Mar; 80():240-246. PubMed ID: 29429908 [TBL] [Abstract][Full Text] [Related]
18. Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy. Porter BE; Jacobson C Epilepsy Behav; 2013 Dec; 29(3):574-7. PubMed ID: 24237632 [TBL] [Abstract][Full Text] [Related]
19. Source of cannabinoids: what is available, what is used, and where does it come from? Specchio N; Pietrafusa N; Cross HJ Epileptic Disord; 2020 Jan; 22(S1):1-9. PubMed ID: 31941643 [TBL] [Abstract][Full Text] [Related]
20. Prospective evaluation of oral cannabis extracts in children with epilepsy. Knupp KG; Rice JD; Helmkamp LJ; Galinkin J; Sempio C; Jost K; Chapman KE Seizure; 2019 Nov; 72():23-27. PubMed ID: 31550641 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]